KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Halozyme Therapeutics (HALO) Income from Continuing Operations (2016 - 2025)

Historic Income from Continuing Operations for Halozyme Therapeutics (HALO) over the last 17 years, with Q4 2025 value amounting to -$141.6 million.

  • Halozyme Therapeutics' Income from Continuing Operations fell 20334.2% to -$141.6 million in Q4 2025 from the same period last year, while for Dec 2025 it was $316.9 million, marking a year-over-year decrease of 2864.82%. This contributed to the annual value of $316.9 million for FY2025, which is 2864.32% down from last year.
  • As of Q4 2025, Halozyme Therapeutics' Income from Continuing Operations stood at -$141.6 million, which was down 20334.2% from $175.2 million recorded in Q3 2025.
  • Halozyme Therapeutics' Income from Continuing Operations' 5-year high stood at $216.6 million during Q3 2021, with a 5-year trough of -$141.6 million in Q4 2025.
  • Its 5-year average for Income from Continuing Operations is $82.4 million, with a median of $79.3 million in 2023.
  • As far as peak fluctuations go, Halozyme Therapeutics' Income from Continuing Operations skyrocketed by 55707.03% in 2021, and later tumbled by 20334.2% in 2025.
  • Halozyme Therapeutics' Income from Continuing Operations (Quarter) stood at $66.8 million in 2021, then decreased by 13.58% to $57.7 million in 2022, then soared by 47.98% to $85.4 million in 2023, then soared by 60.46% to $137.0 million in 2024, then tumbled by 203.34% to -$141.6 million in 2025.
  • Its last three reported values are -$141.6 million in Q4 2025, $175.2 million for Q3 2025, and $165.1 million during Q2 2025.